|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120.06 USD | -2.39% |
|
+1.50% | +20.92% |
| 09:39am | Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating | MT |
| 07-30 | JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 24.93B | |||||
| 75.12B | |||||
| 47.63B | |||||
| 49.48B | |||||
| 42.95B | - | ||||
| 30.72B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
